EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Variant‐Specific Landscape of Mutual Exclusivity Among BRAF , EGFR , and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs

Freya Vaeyens, Jan-Patrick Hetzel, Khaldoon Abdullah, Carolien Eggermont, Catharina Olsen, Marco Mernberger, Ken Maes, Jelle Vlaeminck, Rainer Claus iD, Dries Vanisterbecq, Frederik Hes, Martin Pichler und 3 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Freya Vaeyens und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Clinical Sciences, Research Group Genetics, Reproduction and Developm…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins p21(ras), Mutation, Neoplasms. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel, Deutsche Forschungsgemeinschaft, Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutual exclusivity (ME) and co‐occurrence (CO) of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. We performed a comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes using 64,807 cBioPortal tumor samples, 1570 cancer cell lines, and 2714 Belgian clinical cases. Across all datasets, CO was rare among class I BRAF, hydrolysis KRAS, and classical‐like EGFR mutations. Pairwise variant‐level analyses revealed novel ME interactions, including atypical variants, some overlapping with previously reported synthetically lethal pairs. We functionally validated the ME findings by inducing the expression of EGFR A289V or BRAF V600E in cell lines harboring KRAS G12D or EGFR exon19del , respectively, resulting in growth inhibition. Overall survival analysis showed no consistent prognostic disadvantage for CO, except in EGFR–KRAS co‐mutant NSCLC. These findings further refine the ME landscape of BRAF, KRAS, and EGFR variants, offering a variant‐level reference to support mutation‐informed precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)MutationNeoplasmsHumansErbB ReceptorsCell Line, TumorPrognosis

Stichwörter der Autor:innen

cancer geneticscolorectal cancerfunctional genomicslung cancermutual exclusivity and functional antagonism

Substanzen

Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ErbB ReceptorsKRAS protein, humanBRAF protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Clinical Sciences, Research Group Genetics, Reproduction and Development (GRAD), Centre for Medical Genetics, Brussels, Belgium.
  • Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University, Marburg, Germany.
  • Institute of Innate Immunity, Biomedical Center (Building 13), 1OG 009, University Hospital, University of Bonn, Bonn, Germany.
  • Laboratory of Medical and Molecular Oncology, Oncology Research Center, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
  • Brussels Interuniversity Genomics High Throughput Core (BRIGHTcore), Vrije Universiteit Brussel (VUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Interuniversity Institute of Bioinformatics in Brussels (IB2), Université Libre de Bruxelles - Vrije Universiteit Brussel (ULB-VUB), Brussels, Belgium.

ORCID-Profile: Rainer Claus, Maxim Noeparast

Förderung

  • Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel
  • Deutsche Forschungsgemeinschaft
  • Fonds Wetenschappelijk Onderzoek
  • Universitair Ziekenhuis Brussel
  • Bundesministerium für Bildung und Forschung
  • Bundesministerium für Forschung, Technologie und Raumfahrt

Zitieren

APA

Vaeyens, F., Hetzel, J. P., Abdullah, K., Eggermont, C., Olsen, C., Mernberger, M., Maes, K., Vlaeminck, J., Claus, R., Vanisterbecq, D., Hes, F., Pichler, M., Giron, P., Timofeev, O., & Noeparast, M. (2026). Variant‐Specific Landscape of Mutual Exclusivity Among BRAF , EGFR , and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs. International Journal of Cancer. https://doi.org/10.1002/ijc.70558

Vancouver

Vaeyens F, Hetzel JP, Abdullah K, Eggermont C, Olsen C, Mernberger M, et al. Variant‐Specific Landscape of Mutual Exclusivity Among BRAF , EGFR , and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs. International Journal of Cancer. 2026. doi:10.1002/ijc.70558

BibTeX
@article{Vaeyens2026,
  author = {Vaeyens, Freya and Hetzel, Jan-Patrick and Abdullah, Khaldoon and Eggermont, Carolien and Olsen, Catharina and Mernberger, Marco and Maes, Ken and Vlaeminck, Jelle and Claus, Rainer and Vanisterbecq, Dries and Hes, Frederik and Pichler, Martin and Giron, Philippe and Timofeev, Oleg and Noeparast, Maxim},
  title = {Variant‐Specific Landscape of Mutual Exclusivity Among BRAF , EGFR , and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70558}
}
Kostenlos starten →